GlassScriptPhysician profile
Morgan Nguyen
NPI 1578046777
$4,669.95
in general payments reported to CMS, 2019-2025
15 companies · $1,018 in 2025
The $1,018 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $326 · 2024: $3,327 · 2025: $1,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,222 · Travel and Lodging: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,221.88 |
| Travel and Lodging | $1,448.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,278.68 | 2023-2025 | |
| Genzyme Corporation | $715.81 | 2024-2025 | |
| Galderma Laboratories, L.P. | $248.78 | 2024-2025 | Nemluvio |
| Ucb, INC. | $214.63 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $187.27 | 2024-2025 | Libtayo |
| Kyowa Kirin, INC. | $180.63 | 2024 | Poteligeo |
| E.R. Squibb & Sons, L.L.C. | $173.72 | 2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.91 | 2024-2025 | Spevigo |
| Janssen Biotech, INC. | $146.95 | 2024-2025 | Tremfya |
| Dermavant Sciences, INC. | $111.47 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $109.85 | 2024 | |
| Krystal Biotech INC | $69.45 | 2024 | Vyjuvek |
| Lilly USA, LLC | $25.59 | 2025 | Ebglyss, Taltz, Zepbound |
| Kerecis Limited | $23.06 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Pfizer INC. | $17.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.